AIM: To explore the improvement of visual function and the adverse reactions of retinal laser photocoagulation combined with ranibizumab for the treatment of neovascular glaucoma(NVG), to provide the basis for clinical treatment.

METHODS: One hundred patients with 129 eyes in our hospital from January 2012 to June 2014 were selected. They were randomly divided into the observation group and the control group, 50 cases in each one. Patients in the control group(67 eyes)were treated with retinal laser photocoagulation, and those in the observation group(62 eyes)were given retinal laser photocoagulation combined with ranibizumab treatment. After the treatment, the degeneration of iris neovascularization, visual acuity, intraocular pressure, ocular fundus and the adverse reactions were evaluated. Optical coherence tomography(OCT)was used to detect retinal nerve fiber layer(RNFL)thickness and visual field defect.

RESULTS: The degeneration rate of the iris neovascularization in the observation group was 95.2%(59/62), higher than that of the control group 83.6%(56/67)(P<0.05). The visual acuity of the observation group 4.3～4.7 was 62.9%(39/62), higher than that of the control group 49.3%(33/67); the visual acuity of the observation group ≤4.3 was 25.8%(16/62), lower than that of the control group 43.3%(29/67)(P<0.05). The retinal vein circulation time and intraocular pressure of the observation group after treatments were respectively 8.20±0.41s and 18.50±0.48mmHg, lower than those of the control group 9.42±0.30s and 23.94±0.52mmHg(P<0.05). The degeneration time of the iris neovascularization of the observation group was 6.19±0.27d, which was lower than that of the control group 8.37±0.31d(P<0.05). RNFL thickness of the observation group after treatments was 91.12±2.05μm, higher than that of the control group 85.06±2.19μm; the vision field defect of the observation group after treatments was 13.44±0.59dB, lower than that of the control group 15.92±0.56dB(P<0.05). The difference of adverse reactions between two groups was not statistically significant(P>0.05).

CONCLUSION: The treatment of NVG with laser photocoagulation combined with ranibizumab has good clinical efficacy, and can significantly improve the vision and retinal structure and function of the patients, and is safer.